Name: RMC-7977 **Cat#:** EX-A7974

Chemical Structure:



Chemical Name	3-Oxabicyclo[3.1.0]hexane-6-carboxamide, N-[(2R,14S,18S)-2-[5-(4-cyclopropyl-1-piperazinyl)-2-[(1S)-1-methoxyethyl]-3-pyridinyl]-1-ethyl-18,19,20,21-tetrahydro-25,25-dimethyl-15,22-dioxo-17H-5,3-([4,2]-endo-thiazolopropano[1,3]-endo-pyridazinomethanoxypropano)-1H-indol-14-yl]-, (1α,5α,6α)-

Molecular Weight	865.09	Storage	3 years -20°C powder 6 months -80°C in solvent Away from light
Formula	C47H60N8O6S		
CAS No.	2765082-12-8	Synonyms	RMC 7977; RMC7977

Solubility (25°C) *	In vitro	DMSO	Soluble
		Ethanol	N/A
		Water	N/A
	In vivo (should be freshly prepared each time)		

* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Preparing Stock Solutions:

Mass / Volume / Concentration	1 mg	5 mg	10 mg
1 mM	1.1559 mL	5.7797 mL	11.5595 mL
5 mM	0. 2312 mL	1.1559 mL	2.3119 mL
10 mM	0. 1156 mL	0. 5780 mL	1.1559 mL

*The above data is based on the product molecular weight 865.09.

Biological Activities:

Description	RMC-7977 is a reversible, tri-complex RAS inhibitor with broad spectrum activity for both mutant and wild-type (WT) KRAS, NRAS, and HRAS variants. RMC-7977 can lead to tumor regressions and was well tolerated in diverse RAS-addicted preclinical cancer models. RMC-7977 also can inhibit the growth of $KRAS^{G12C}$ cancer models[1].

References	[1]. Singh M, et al. Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy. Research Square; 2023.